10-Q
Quarterly Report
60 DEGREES PHARMACEUTICALS, INC.
SXTPW
NASDAQ
CIK: 1946563
File #: 001-41719
Balance Sheet
45 line items · 2 periods
XBRL
| Item | Mar 31, 2025 | Dec 31, 2024 |
|---|---|---|
Current Assets: | ||
Cash and Cash Equivalents | 3,451,500 | 1,659,353 |
Accounts Receivable | 488,243 | 486,748 |
Prepaid and Other Assets | 937,250 | 1,068,940 |
Short-Term Investments | — | 1,728,472 |
Inventory (Note 3) | 773,238 | 442,764 |
Total Current Assets | 5,650,231 | 5,386,277 |
Property and Equipment, net (Note 4) | 155,792 | 149,808 |
Other Assets: | ||
Long-Term Prepaid Expense | 22,059 | 66,176 |
Intangible Assets, net (Note 5) | 149,785 | 157,084 |
Total Other Assets | 171,844 | 223,260 |
Total Assets | 5,977,867 | 5,759,345 |
LIABILITIES AND SHAREHOLDERS’ EQUITY: | ||
Current Liabilities: | ||
Accounts Payable and Accrued Expenses | 1,157,979 | 1,007,618 |
SBA EIDL (including accrued interest) (Note 7) | 8,772 | 8,772 |
Derivative Liabilities (Note 8) | 635,725 | 640,830 |
Fair Value, Inputs, Level 3 - Derivative Liabilities | 635,725 | — |
Derivative Liabilities | 635,725 | — |
Fair Value, Inputs, Level 3 | 635,725 | — |
Contingent Milestone Payment - Fair Value, Inputs, Level 3 - Fair Value, Recurring | 635,725 | 640,830 |
Fair Value, Inputs, Level 3 - Fair Value, Recurring | 635,725 | 640,830 |
Total Current Liabilities | 1,802,476 | 1,657,220 |
Long-Term Liabilities: | ||
SBA EIDL (including accrued interest) (Note 7) | 146,502 | 147,119 |
Total Long-Term Liabilities | 146,502 | 147,119 |
Total Liabilities | 1,948,978 | 1,804,339 |
SHAREHOLDERS’ EQUITY: | ||
Series A Preferred Stock, $0.0001 par value, 1,000,000 shares authorized; 76,480 and 76,480 issued and outstanding as of March 31, 2025 and December 31, 2024, respectively (Note 6) | 9,567,439 | 9,567,439 |
Common Stock, $0.0001 par value, 150,000,000 shares authorized; 1,472,891 and 566,908 issued and outstanding as of March 31, 2025 and December 31, 2024, respectively (Note 6) | 147 | 57 |
Additional Paid-in Capital | 36,821,588 | 34,860,590 |
Accumulated Other Comprehensive Income | 125,567 | 135,471 |
Accumulated Deficit | (42,404,506) | (40,527,957) |
60P Shareholders’ Equity: | 4,110,235 | 4,035,600 |
Noncontrolling Interest | (81,346) | (80,594) |
Total Shareholders’ Equity | 4,028,889 | 3,955,006 |
Series A - Preferred Stock | 9,567,439 | 9,567,439 |
Common Stock | 147 | 57 |
Additional Paid-In Capital | 36,821,588 | 34,860,590 |
Accumulated Deficit | (42,404,506) | (40,527,957) |
Accumulated Other Comprehensive Income (Loss) | 125,567 | 135,471 |
Total Shareholders’ Equity (Deficit) Attributable to 60P | 4,110,235 | 4,035,600 |
Noncontrolling Interest on Shareholders | (81,346) | (80,594) |
Total Liabilities and Shareholders’ Equity | 5,977,867 | 5,759,345 |